<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03547544</url>
  </required_header>
  <id_info>
    <org_study_id>18-04-0394</org_study_id>
    <nct_id>NCT03547544</nct_id>
  </id_info>
  <brief_title>Rapid Urease Test for Diagnosis Helicobacter Pylori Infection</brief_title>
  <official_title>Effectiveness of Rapid Urease Test (Helicotec) for The Diagnosis of Helicobacter Pylori Infection in Dyspepsia Patients in Endoscopy Centre</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indonesia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indonesia University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nowadays, the gold standard examinations for diagnosing H. pylori infection are
      histopathology and culture examination. However, those examinations take long preparation so
      they are not suitable to be applied in daily practice. In progress, another examination is
      being developed to detect urease enzyme from tissue biopsy. It is relatively faster in
      diagnosing H. Pylori infection. Some commercial urease tests which are available in Indonesia
      are Helicotec速 and Pronto Dry速.

      This study aims to determine the effectivity of Helicotec速 in diagnosing H. pylori infection.
      It is expected to be scientific evidence that can be used as the basis daily routine of
      urease test in diagnosing H. Pylori infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a diagnostic study. There will be 97 dyspepsia patients who met the inclusion
      and exclusion criteria. They will answer the questionnaire about personal data and examined
      physically. They will also undergo endoscopy, biopsy, and urease test using Helicotec速
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">May 28, 2018</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Effectivity of Helicotec</measure>
    <time_frame>1 day</time_frame>
    <description>Obtained the sensitivity and specificity value</description>
  </primary_outcome>
  <enrollment type="Anticipated">97</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <eligibility>
    <study_pop>
      <textblock>
        General population: Jakarta citizen Targeted population: Patients of endoscopy centre Cipto
        Mangunkusumo Hospital Sample: Targeted population who undergo endoscopy examination and met
        the inclusion and exclusion criteria
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult (18-55 years old),

          -  Diagnosed with dyspepsia,

          -  Indicated for endoscopy,

          -  Agreed to participate in the study and signed the informed consent.

        Exclusion Criteria:

          -  Pregnancy and breastfeeding woman,

          -  Patients with alarm symptom,

          -  History taking of antibiotics (amoxicillin, clarithromycin, levofloxacin), H2 receptor
             antagonist, proton pump inhibitor, misoprostol, sucralfat, bismuth, NSAIDs, steroid,
             rheumatoid drug within the last 2 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ari F Syam, Dr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gastroenterology Division, Internal Medicine Department RSCM/UI</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ari F Syam, Dr, MD</last_name>
    <phone>+62818706199</phone>
    <email>ari_syam@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cipto Mangunkusumo Hospital</name>
      <address>
        <city>Jakarta Pusat</city>
        <state>DKI Jakarta</state>
        <zip>10430</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ari F Syam, Dr, MD</last_name>
      <phone>+62818706199</phone>
      <email>ari_syam@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Ari F Syam, Dr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Murdani Abdullah, Prof, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dadang Makmun, Prof, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hasan Maulahela, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>May 23, 2018</study_first_submitted>
  <study_first_submitted_qc>June 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2018</study_first_posted>
  <last_update_submitted>June 4, 2018</last_update_submitted>
  <last_update_submitted_qc>June 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indonesia University</investigator_affiliation>
    <investigator_full_name>Ari Fahrial Syam</investigator_full_name>
    <investigator_title>Staff of Gastroenterology Division, Internal Medicine Department</investigator_title>
  </responsible_party>
  <keyword>helicobacter pylori</keyword>
  <keyword>urease test</keyword>
  <keyword>helicotec</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

